Administration of Anti-SARS-CoV-2 Convalescent Plasma in Hospitalized, Non-ICU Patients With COVID-19
Status:
Withdrawn
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and safety of the administration of
anti-SARS-CoV-2 convalescent plasma in COVID-19 patients who are sick enough to warrant
hospitalization, but not yet admitted to the ICU (prior to the onset of overwhelming disease
including a systemic inflammatory response, sepsis, and/or ARDS).